Drugs / Xerecept
Xerecept
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01369121 | Jun 2010 → Oct 2012 | brain edema, brain neoplasm | Celtic Pharma Development Services | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00691522 | Nov 2008 → Aug 2009 | brain cancer, brain edema | PharmaNet | Terminated | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT00226668 | Jan 2006 → Jan 2008 | brain edema, brain glioma | Celtic Pharma Development Services | Withdrawn | No outcome recorded |
| Phase 3 | NCT00226655 | Jul 2005 → Mar 2009 | brain edema, brain neoplasm | Celtic Pharma Development Services | Completed | No outcome recorded |
| Phase 3 | NCT00088166 | May 2004 → Mar 2008 | brain edema, brain neoplasm | Celtic Pharma Development Services | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT02316132 | Dec 2014 → Jun 2016 | irritable bowel syndrome | University Hospital Schleswig-Holstein | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT04037605 Background | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00820092 Comparator | Dec 2008 → Mar 2009 | — | Celtic Pharma Development Services | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xerecept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00691522 ↗ |
| Known as | Acthrel | “Corticorelin (also known as Acthrel)” NCT04037605 ↗ |
| Known as | Corticorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03142893 ↗ |
| Known as | corticorelin acetate | “PURPOSE: To compare the safety and efficacy of corticorelin acetate (CrA) and placebo in patients with malignant brain tumors requiring chronic administration of dexamethasone...” PMID 23382470 ↗ Feb 2013 |
| Known as | Corticotropin-Releasing Hormone | “Corticotropin-Releasing Hormone” NCT02316132 ↗ |
| Known as | hCRF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00226655 ↗ |
| Known as | hCRF, XERECEPT (corticorelin acetate injection) | “hCRF, XERECEPT (corticorelin acetate injection)” NCT00226655 ↗ |
| Known as | XERECEPT (corticorelin acetate injection); hCRF | “XERECEPT (corticorelin acetate injection); hCRF” NCT00088166 ↗ |
| Route | Subcutaneous | “One hundred patients received subcutaneous injections of 1 mg twice per day of CrA and 100 patients received placebo for the duration of the study period.” PMID 23382470 ↗ Feb 2013 |